Clinical trial
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With…
NCT00061750 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00061750 |
|---|---|
| Title | Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions |
| Official title | A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Beta-Thalassemia |
| Intervention type | Drug |
| Interventions | ICL670, deferoxamine |
| Enrollment | 595 |
| Start date | May 1, 2003 |
| Primary completion | Nov 1, 2004 |
| First posted | Jun 4, 2003 |
| Last update posted | Apr 19, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: